Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

Rikova, Klarisa; Guo, Ailan; Zeng, Qingfu; Possemato, Anthony; Yu, Jian; Haack, Herbert; Nardone, Julie; Lee, Kimberly; Reeves, Cynthia; Li, Yu; Hu, Yerong; Tan, Zhiping; Stokes, Matthew; Sullivan, Laura; Mitchell, Jeffrey; Wetzel, Randy; MacNeill, Joan; Ren, Jian Min; Yuan, Jin; Bakalarski, Corey E.; Villen, Judit; Kornhauser, Jon M.; Smith, Bradley; Li, Daiqiang; Zhou, Xinmin; Gygi, Steven P.; Gu, Ting-Lei; Polakiewicz, Roberto D.; Rush, John; Comb, Michael J.

doi:10.1016/j.cell.2007.11.025

Cited by 2,317Lung Cancer Treatments and MutationsAdvanced Proteomics Techniques and ApplicationsLung Cancer Research Studies

Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

Open access

Rikova, Klarisa, Guo, Ailan, Zeng, Qingfu, Possemato, Anthony, Yu, Jian, Haack, Herbert, Nardone, Julie, Lee, Kimberly +22 more·2007·Cell

DOI 10.1016/j.cell.2007.11.025

Open this paper in CoChat — free account Open PDF

Abstract

Despite the success of tyrosine kinase-based cancer therapeutics, for most solid tumors the tyrosine kinases that drive disease remain unknown, limiting our ability to identify drug targets and predict response. Here we present the first large-scale survey of tyrosine kinase activity in lung cancer. Using a phosphoproteomic approach, we characterize tyrosine kinase signaling across 41 non-small cell lung cancer (NSCLC) cell lines and over 150 NSCLC tumors. Profiles of phosphotyrosine signaling are generated and analyzed to identify known oncogenic kinases such as EGFR and c-Met as well as novel ALK and ROS fusion proteins. Other activated tyrosine kinases such as PDGFRalpha and DDR1 not previously implicated in the genesis of NSCLC are also identified. By focusing on activated cell circuitry, the approach outlined here provides insight into cancer biology not available at the chromosomal and transcriptional levels and can be applied broadly across all human cancers.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2007.11.025

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

ROS1 fusions are rare genetic events reported in multiple solid tumors, including NSCLC, with prevalence 0.9% to 2.6%.
“These ROS1 fusions are rare genetic events reported in multiple solid tumors, including non–small cell lung cancer (NSCLC), where the prevalence is 0.9% to 2.6%.1,3-5”
From Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST (2025) · cites this paper as [3]
ALK gene rearrangements are identified in a small proportion of newly diagnosed patients with NSCLC (approximately 5%).
“ALK gene rearrangements are identified in a small proportion of newly diagnosed patients with NSCLC (approximately 5%).77,87–89”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [87]

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works
Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics
Ong, S.-E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., & Mann, M. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m200025-mcp200 · Cited by 5,574 · see citing works
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · see citing works
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435 · see citing works
TM4: a free, open-source system for microarray data management and analysis
Saeed, A. I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M., et al. (2003) · BioTechniques · doi:10.2144/03342mt01 · Cited by 4,837 · see citing works
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,245 · see citing works
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · see citing works
Oncogenic kinase signalling.
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738 · see citing works
Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks
Olsen, J. V., Blagoev, B., Gnad, F., Maček, B., Kumar, C., Mortensen, P., & Mann, M. (2006) · Cell · doi:10.1016/j.cell.2006.09.026 · Cited by 3,484 · see citing works
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,191 · see citing works
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,062 · see citing works
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713 · see citing works
A Model for Random Sampling and Estimation of Relative Protein Abundance in Shotgun Proteomics
Liu, H., Sadygov, R. G., & Yates, J. R. (2004) · Analytical Chemistry · doi:10.1021/ac0498563 · Cited by 2,486 · see citing works
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,404 · see citing works
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,753 · see citing works
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442 · see citing works
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A. V., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,288 · see citing works
Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics
Old, W. M., Meyer-Arendt, K., Aveline-Wolf, L. D., Pierce, K. G., Mendoza, A. M., Sevinsky, J. R., Resing, K. A., & Ahn, N. G. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500084-mcp200 · Cited by 1,206 · see citing works
MIF Signal Transduction Initiated by Binding to CD74
Leng, L., Metz, C. N., Fang, Y., Xu, J., Donnelly, S., Baugh, J., Delohery, T., Chen, Y., Mitchell, R. A., & Bucala, R. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030286 · Cited by 1,154 · see citing works
Immunoaffinity profiling of tyrosine phosphorylation in cancer cells
Rush, A. J., Moritz, A., Lee, K. A., Guo, A., Goss, V. L., Spek, E. J., Zhang, H., Zha, X., Polakiewicz, R. D., & Comb, M. J. (2004) · Nature Biotechnology · doi:10.1038/nbt1046 · Cited by 1,126 · see citing works
Self-citation
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., Debiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 978 · see citing works
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915 · see citing works
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802 · see citing works
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance
Mahon, F., Deininger, M. W., Schultheis, B. S., Chabrol, J., Reiffers, J. J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 776 · see citing works
PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation
Hornbeck, P. V., Chabra, I., Kornhauser, J. M., Skrzypek, E., & Zhang, B. (2004) · PROTEOMICS · doi:10.1002/pmic.200300772 · Cited by 590 · see citing works
Self-citation
Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer
Ma, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M., Nallasura, V., Fox, E. A., Hansen, M., SCHAEFER, E. M., Naoki, K., Lader, A. S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2650 · Cited by 576 · see citing works
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 539 · see citing works
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
Engelman, J. A., Janne, P. A., Mermel, C. H., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K. M., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 494 · see citing works
Quantitative Proteomics Analysis of the Secretory Pathway
Gilchrist, A., Au, C. E., Hiding, J., Bell, A. W., Fernández-Rodrı́guez, J., Lesimple, S., Nagaya, H., Roy, L., Gosline, S. J. C., Hallett, M. T., et al. (2006) · Cell · doi:10.1016/j.cell.2006.10.036 · Cited by 457 · see citing works
Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer
Amann, J. M., Kalyankrishna, S., Massion, P. P., Ohm, J. E., Girard, L., Shigematsu, H., Peyton, M., Juroske, D. M., Huang, Y., Salmon, J. S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.226.65.1 · Cited by 432 · see citing works
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
Tracy, S. I., Mukohara, T., Hansen, M., Meyerson, M. M., Johnson, B. E., & Janne, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1905 · Cited by 368 · see citing works
Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer
Mitelman, F., Johansson, B., & Mertens, F. (2004) · Nature Genetics · doi:10.1038/ng1335 · Cited by 361 · see citing works
Correlation of Relative Abundance Ratios Derived from Peptide Ion Chromatograms and Spectrum Counting for Quantitative Proteomic Analysis Using Stable Isotope Labeling
Zybailov, B. L., Coleman, M. K., Florens, L. A., & Washburn, M. P. (2005) · Analytical Chemistry · doi:10.1021/ac050846r · Cited by 349 · see citing works
Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Walters, D. K., Mercher, T., Gu, T., O'Hare, T., Tyner, J., Loriaux, M., Goss, V., Lee, K. A., Eide, C., Wong, M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.002 · Cited by 347 · see citing works
Self-citation
Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
Zhang, P., Gao, W., Turner, S., & Ducatman, B. S. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-1 · Cited by 343 · see citing works
Lung Cancer Cell Lines Harboring MET Gene Amplification Are Dependent on Met for Growth and Survival
Lutterbach, B. A., Zeng, Q., Davis, L. J., Hatch, H., Hang, G., Kohl, N. E., Gibbs, W. W., & Pan, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3495 · Cited by 321 · see citing works
Self-citation
TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally DifferentTFG-ALK Translocations
Hernández, L., Pinyol, M., Hernandez, S. F., Beà, S., Pulford, K. A. F., Rosenwald, A., Lamant, L., Falini, B., Ott, G., Mason, D. Y., et al. (1999) · Blood · doi:10.1182/blood.v94.9.3265 · Cited by 285 · see citing works
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
Mahadevan, D., Cooke, L. S., Riley, C., Swart, R. E., Simons, B. W., Croce, K. D., Wisner, L., Iorio, M. V., Shakalya, K., Garewal, H. S., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210173 · Cited by 283 · see citing works
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration
Wolf‐Yadlin, A., Kumar, N., Zhang, Y., Hautaniemi, S., Zaman, M. H., Kim, H., Grantcharova, V., Lauffenburger, D. A., & White, F. M. (2006) · Molecular Systems Biology · doi:10.1038/msb4100094 · Cited by 247 · see citing works
Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.
Kinch, M. S., Moore, M.-B. H., & Harpole, D. H. (2003) · PubMed · Cited by 235 · see citing works
A Secreted Form of ADAM9 Promotes Carcinoma Invasion through Tumor-Stromal Interactions
Mazzocca, A., Coppari, R., Franco, R. D., Cho, J., Libermann, T. A., Pinzani, M., & Toker, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4449 · Cited by 191 · see citing works
ROS Fusion Tyrosine Kinase Activates a SH2 Domain–Containing Phosphatase-2/Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Signaling Axis to Form Glioblastoma in Mice
Charest, A., Wilker, E., McLaughlin, M. E., Lane, K. M., Gowda, R., Coven, S., McMahon, K., Kovach, S., Feng, Y., Yaffe, M. B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1193 · Cited by 164 · see citing works
Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma
Ford, C. E., Lau, S. A., Zhu, C., Andersson, T., Tsao, M., & Vogel, W. F. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603614 · Cited by 142 · see citing works
RIN1 Is an ABL Tyrosine Kinase Activator and a Regulator of Epithelial-Cell Adhesion and Migration
Hu, H., Bliss, J. M., Wang, Y., et al. (2005) · Current Biology · doi:10.1016/j.cub.2005.03.049 · Cited by 122 · see citing works
Critical Function for ADAM9 in Mouse Prostate Cancer
Peduto, L., Reuter, V. E., Shaffer, D. R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1063 · Cited by 116 · see citing works
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
Minami, Y., Shimamura, T., Shah, K., LaFramboise, T., Glatt, K. A., Liniker, E., Borgman, C. L., Haringsma, H. J., Feng, W. W., Weir, B. A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210292 · Cited by 109 · see citing works
Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas
Hernández, L., Beà, S., Bellosillo, B., Pinyol, M., Falini, B., Carbone, A., Ott, G., Rosenwald, A., Fernández, A., Pulford, K. A. F., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62574-6 · Cited by 107 · see citing works
Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia
Gu, T.-L., Goss, V. L., Reeves, C., Popova, L., Nardone, J., MacNeill, J., Walters, D. K., Wang, Y., Rush, A. J., Comb, M. J., et al. (2006) · Blood · doi:10.1182/blood-2006-06-026666 · Cited by 76 · see citing works
Self-citation
Enhanced Analysis of Metastatic Prostate Cancer Using Stable Isotopes and High Mass Accuracy Instrumentation
Everley, P. A., Bakalarski, C. E., Elias, J. E., Waghorne, C. G., Beausoleil, S. A., Gerber, S. A., Faherty, B. K., Zetter, B. R., & Gygi, S. P. (2006) · Journal of Proteome Research · doi:10.1021/pr0504891 · Cited by 72 · see citing works
Self-citation
Interleukin-2-induced survival of natural killer (NK) cells involving phosphatidylinositol-3 kinase-dependent reduction of ceramide through acid sphingomyelinase, sphingomyelin synthase, and glucosylceramide synthase
Taguchi, Y., Kondo, T., Watanabe, M., Miyaji, M., Umehara, H., Kozutsumi, Y., & Okazaki, T. (2004) · Blood · doi:10.1182/blood-2004-03-0900 · Cited by 52 · see citing works
Chasing Mutations in the Epidermal Growth Factor in Lung Cancer
Dowell, J. E., & Minna, J. D. (2005) · New England Journal of Medicine · doi:10.1056/nejme058033 · Cited by 32 · see citing works

Flagged first, then by citations

Sorted by citations

The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891 · see citing works
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · see citing works
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190 · see citing works
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220 · see citing works
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · see citing works
SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation
Hirschey, M. D., Shimazu, T., Goetzman, E., Jing, E., Schwer, B., Lombard, D. B., Grueter, C. A., Harris, C., Biddinger, S., Ilkayeva, O. R., et al. (2010) · Nature · doi:10.1038/nature08778 · Cited by 1,687 · see citing works
Self-citation
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555 · see citing works
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407 · see citing works
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320 · see citing works
PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity
Kane, L. A., Lazarou, M., Fogel, A. I., Li, Y., Yamano, K., Sarraf, S. A., Banerjee, S., & Youle, R. J. (2014) · Journal of Cell Biology · doi:10.1083/jcb.201402104 · Cited by 1,298 · see citing works
Self-citation
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280 · see citing works
Proteomics by Mass Spectrometry: Approaches, Advances, and Applications
Yates, J. R., Ruse, C. I., & Nakorchevsky, A. (2009) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-061008-124934 · Cited by 1,078 · see citing works
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083 · see citing works
The increasing complexity of the ubiquitin code
Yau, R., & Rape, M. (2016) · Nature Cell Biology · doi:10.1038/ncb3358 · Cited by 1,054 · see citing works
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968 · see citing works
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962 · see citing works
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886 · see citing works
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850 · see citing works
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30649-1 · Cited by 791 · see citing works
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
Shaw, A. T., Riely, G. J., Bang, Y.-J., Kim, D.-W., Camidge, D. R., Solomon, B. J., Varella-Garcia, M., Iafrate, A. J., Shapiro, G. I., Usari, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz131 · Cited by 576 · see citing works
PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4055 · Cited by 504 · see citing works
SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production
Shimazu, T., Hirschey, M. D., Hua, L., Dittenhafer-Reed, K. E., Schwer, B., Lombard, D. B., Li, Y., Bunkenborg, J., Alt, F. W., Denu, J. M., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.11.003 · Cited by 484 · see citing works
Self-citation
Modification‐specific proteomics: Strategies for characterization of post‐translational modifications using enrichment techniques
Zhao, Y., & Jensen, O. N. (2009) · PROTEOMICS · doi:10.1002/pmic.200900398 · Cited by 384 · see citing works
Genetic alterations defining NSCLC subtypes and their therapeutic implications
Pikor, L. A., Ramnarine, V. R., Lam, S., & Lam, W. L. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.025 · Cited by 375 · see citing works
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Yoda, S., Lin, J. J., Lawrence, M. S., Burke, B. J., Friboulet, L., Langenbucher, A., Dardaei, L., Prutisto-Chang, K., Dagogo-Jack, I., Timofeevski, S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1256 · Cited by 322 · see citing works
Post-translational modifications of Hsp90 and their contributions to chaperone regulation
Mollapour, M., & Neckers, L. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.07.018 · Cited by 288 · see citing works
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Hantschel, O., Rix, U., & Superti-Furga, G. (2008) · Leukemia & Lymphoma · doi:10.1080/10428190801896103 · Cited by 256 · see citing works
Treating ALK-positive lung cancer—early successes and future challenges
Camidge, D. R., & Doebele, R. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.43 · Cited by 236 · see citing works
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
Spigel, D. R., Reynolds, C., Waterhouse, D., Garon, E. B., Chandler, J., Babu, S., Thurmes, P., Spira, A., Jotte, R., Zhu, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.022 · Cited by 229 · see citing works
Molecular pathways and therapeutic targets in lung cancer
Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220 · see citing works
“The fusions of ROS with SLC34A2 and CD74 were identified in a phosphoproteomic screen of tyrosine kinase activity in lung cancer [115], and have been observed predominantly in AC [116, 117].”
Background
Cancer cell signaling pathways targeted by spice-derived nutraceuticals
Sung, B., Prasad, S., Yadav, V. R., & Aggarwal, B. B. (2012) · Nutrition and Cancer · doi:10.1080/01635581.2012.630551 · Cited by 204 · see citing works
Performance Metrics for Liquid Chromatography-Tandem Mass Spectrometry Systems in Proteomics Analyses
Rudnick, P. A., Clauser, K. R., Kilpatrick, L. E., Tchekhovskoi, D. V., Neta, P., Blonder, N., Billheimer, D. D., Blackman, R. K., Bunk, D. M., Cardasis, H. L., et al. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900223-mcp200 · Cited by 183 · see citing works
Global proteomic assessment of the classical protein-tyrosine phosphatome and “Redoxome”
Karisch, R., Fernandez, M., Taylor, P., Virtanen, C., St-Germain, J. R., Jin, L. L., Harris, I. S., Mori, J., Mak, T. W., Senis, Y. A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.020 · Cited by 179 · see citing works
Lactoferrin, a Pleiotropic Protein in Health and Disease
Mayeur, S., Spahis, S., Pouliot, Y., & Levy, E. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6458 · Cited by 145 · see citing works
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer
Lin, J. J., Choudhury, N. J., Yoda, S., Zhu, V. W., Johnson, T. W., Sakhtemani, R., Dagogo-Jack, I., Digumarthy, S. R., Lee, C., Do, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0032 · Cited by 145 · see citing works
Fusion genes and chromosome translocations in the common epithelial cancers
Edwards, P. A. (2010) · The Journal of Pathology · doi:10.1002/path.2632 · Cited by 126 · see citing works
ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
Gendarme, S., Bylicki, O., Chouaid, C., & Guisier, F. (2022) · Current Oncology · doi:10.3390/curroncol29020057 · Cited by 121 · see citing works
Quantitative Phosphoproteomics Reveals a Cluster of Tyrosine Kinases That Mediates Src Invasive Activity in Advanced Colon Carcinoma Cells
Leroy, C., Fialin, C., Sirvent, A., Simon, V., Urbach, S., Poncet, J., Robert, B., Jouin, P., & Roche, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2354 · Cited by 114 · see citing works
Comprehensive Dissection of PDGF-PDGFR Signaling Pathways in PDGFR Genetically Defined Cells
Wu, E., Palmer, N., Tian, Z., Moseman, A. P., Galdzicki, M., Wang, X., Berger, B., Zhang, H., & Kohane, I. S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003794 · Cited by 118 · see citing works
ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties
Childress, M. A., Himmelberg, S. M., Chen, H., Deng, W., Davies, M. A., & Lovly, C. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0171 · Cited by 108 · see citing works
Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.
Mahajan, K., & Mahajan, N. P. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22162 · Cited by 92 · see citing works
Commonality but Diversity in Cancer Gene Fusions
Rabbitts, T. H. (2009) · Cell · doi:10.1016/j.cell.2009.04.034 · Cited by 73 · see citing works
Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity
Mollapour, M., Tsutsumi, S., Kim, Y. S., Trepel, J., & Neckers, L. (2011) · Oncotarget · doi:10.18632/oncotarget.272 · Cited by 66 · see citing works
Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST
Pérol, M., Li, W., Pennell, N. A., Liu, G., Ohe, Y., De Braud, F., Nagasaka, M., Felip, E., Xiong, A., Zhang, Y., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00275 · Cited by 63 · see citing works
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Drilon, A., Horan, J. C., Tangpeerachaikul, A., Besse, B., Ou, S.-H. I., Gadgeel, S. M., Camidge, D. R., van der Wekken, A. J., Nguyen-Phuong, L., Acker, A., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0968 · Cited by 52 · see citing works
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39 · see citing works
Advances and future directions in ROS1 fusion-positive lung cancer
Boulanger, M. C., Schneider, J. L., & Lin, J. J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae205 · Cited by 38 · see citing works
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells
Amin, A. D., Rajan, S. S., Groysman, M. J., Pongtornpipat, P., & schatz, J. H. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s29326 · Cited by 25 · see citing works
A wide-ranging cellular response to UV damage of DNA
Stokes, M., & Comb, M. (2008) · Cell Cycle · doi:10.4161/cc.7.14.6326 · Cited by 21 · see citing works
Self-citation

ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ
Атабекова, Б. Б. (2024) · Habaršy. Pedagogika ġylymdary seriâsy · doi:10.51889/2959-5762.2023.80.4.019
Molecular Epidemiology of Female Lung Cancer
Yim, S., & Chung, Y. (2011) · Cancers · doi:10.3390/cancers3021861 · Cited by 11 · see citing works
The Expression and Clinical Significance of Adrenomedulin in Patients with Lung Cancer
Shaoguang, H. (2006) · Zhongguo linchuang yixue
Electrochemical biosensors for the detection of lung cancer biomarkers: A review
Khanmohammadi, A., Aghaie, A. B. G., Vahedi, E., Qazvini, A., Ghanei, M., Afkhami, A., Hajian, A., & Bagheri, H. (2019) · Talanta · doi:10.1016/j.talanta.2019.120251 · Cited by 358 · see citing works
[Gender-associated differences of lung cancer and mechanism].
Xing, X., Liao, Y., Tang, H., Chen, G., Ju, S., & You, L. (2011) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2011.07.12 · Cited by 3 · see citing works

Authors: Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., Hu, Y., Tan, Z., Stokes, M., Sullivan, L., Mitchell, J., Wetzel, R., MacNeill, J., Ren, J. M., Yuan, J., Bakalarski, C. E., Villen, J., Kornhauser, J. M., Smith, B., Li, D., Zhou, X., Gygi, S. P., Gu, T.-L., Polakiewicz, R. D., Rush, J., & Comb, M. J.
Affiliations: Cell Signaling Technology (United States) (US)
Central South University (CN)
Harvard University (US)
Corresponding author: Comb, Michael J.
ORCID: Guo, Ailan
Zeng, Qingfu
Possemato, Anthony
Lee, Kimberly
Li, Yu
Hu, Yerong
Tan, Zhiping
Stokes, Matthew
Sullivan, Laura
Ren, Jian Min
Bakalarski, Corey E.
Smith, Bradley
Li, Daiqiang
Gygi, Steven P.
Venue: Cell
Publisher: Elsevier BV
Published: 2007-12
Volume: 131
Issue: 6
Pages: 1190-1203
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2007.11.025
OpenAlex: W2168691181
Cited by: 2,317
References: 54
Citations by year: 2026: 30 · 2025: 53 · 2024: 53 · 2023: 93 · 2022: 91 · 2021: 115 · 2020: 121 · 2019: 102 · 2018: 117 · 2017: 144 · 2016: 161 · 2015: 176 · 2014: 213 · 2013: 213 · 2012: 207
FWCI: 79.24
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2091 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: phosphotyrosine signaling, tyrosine kinase activity, non-small cell lung cancer, oncogenic kinase, phosphoproteomics, EGFR, c-Met, ALK fusion proteins, PDGFRA, DDR1, kinase signaling networks, drug target identification
MeSH terms: Anaplastic Lymphoma Kinase, Carcinoma, Non-Small-Cell Lung, Enzyme Activation, Humans, Lung Neoplasms, Models, Biological, Molecular Sequence Data, Phosphorylation, Protein-Tyrosine Kinases, Signal Transduction, Phosphotyrosine, Receptor Protein-Tyrosine Kinases, Receptor, Platelet-Derived Growth Factor alpha, Cell Line, Tumor, Gene Fusion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks